Marie Curie Chair-Planning grant application
| Reference number | |
| Coordinator | Karolinska institutet - Stockholm Brain Institute |
| Funding from Vinnova | SEK 50 000 |
| Project duration | April 2011 - October 2011 |
| Status | Completed |
Purpose and goal
The research will focus on target identification for development of therapeutic agents for HD. Dr. Becanovic is the project leader and will work with Dr. Svenningson and Dr. Tedroff, both experts in the field of HD and with Prof. Forssberg who is the director of SBI. Research will be conducted to investigate the effects of ACR-16 (Huntexil®), a promising novel treatment for HD, on pre- and post-synaptic dopamine and glutamate transmission. Further research will be conducted to evaluate the effects of ACR-16 on disease progression in transgenic animal models of HD.